Indegene Past Earnings Performance
Past criteria checks 5/6
Indegene has been growing earnings at an average annual rate of 28.4%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 26.9% per year. Indegene's return on equity is 23.6%, and it has net margins of 13%.
Key information
28.4%
Earnings growth rate
26.1%
EPS growth rate
Life Sciences Industry Growth | 11.2% |
Revenue growth rate | 26.9% |
Return on equity | 23.6% |
Net Margin | 13.0% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Indegene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 25,896 | 3,367 | 16,516 | 0 |
31 Dec 23 | 25,489 | 2,907 | 16,452 | 0 |
31 Mar 23 | 23,061 | 2,661 | 14,687 | 0 |
31 Mar 22 | 16,646 | 1,648 | 10,222 | 0 |
31 Mar 21 | 9,806 | 1,857 | 5,403 | 0 |
31 Mar 20 | 6,436 | 558 | 3,738 | 0 |
Quality Earnings: 544172 has high quality earnings.
Growing Profit Margin: 544172's current net profit margins (13%) are higher than last year (11.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 544172's earnings have grown significantly by 28.4% per year over the past 5 years.
Accelerating Growth: 544172's earnings growth over the past year (26.5%) is below its 5-year average (28.4% per year).
Earnings vs Industry: 544172 earnings growth over the past year (26.5%) exceeded the Life Sciences industry 9.8%.
Return on Equity
High ROE: 544172's Return on Equity (23.6%) is considered high.